Emerging cardiovascular technology, trends in ambulatory care, provider and payer partnerships, and value-based arrangements create strategic opportunities to address service demand and cost pressures ...

Please provide your email address to receive an email when new articles are posted on . The European and UK markets will have access to the CLAiR technology from Toku. CLAiR assesses cardiovascular ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. One person dies of cardiovascular disease (CVD) every 34 ...

Modern cardiovascular care involves human acumen, complex data and collaborative intelligence between the two. Payment models are based on well-defined tests and procedures and are baffled by the ...

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings Inc. (Nasdaq: CDIO), an artificial intelligence-powered precision cardiovascular medicine company, today announced that the Japan Patent Office ...

Toku’s AI (CLAiR) technology platform has received FDA Breakthrough Device status, and if cleared by the FDA will deliver real-time cardiovascular disease (CVD) risk assessments through routine eye ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. For many hospitals, it’s a high-stakes scramble to keep ...

Boston Scientific BSX, a prominent global player in cardiovascular technology, is well-positioned to capitalize on the robust expansion of the cardiovascular devices market. According to a ...

Before selecting any clinical treatment or modality, a comprehensive and also unbiased review and understanding of the clinical evidence is critical for the best patient outcomes. Three examples of ...

A new position statement from the Cardiac Society of Australia and New Zealand (CSANZ) and the Australian Cardiovascular Health and Rehabilitation Association (ACRA) underscores telehealth as a ...